Compare AVAH & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAH | INVA |
|---|---|---|
| Founded | 1984 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2021 | 2000 |
| Metric | AVAH | INVA |
|---|---|---|
| Price | $6.47 | $23.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $9.75 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 1.0M | 508.3K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1850.00 | 816.67 |
| EPS | 1.05 | ★ 3.30 |
| Revenue | ★ $2,433,199,000.00 | $217,217,000.00 |
| Revenue This Year | $7.31 | $8.95 |
| Revenue Next Year | $5.59 | $12.65 |
| P/E Ratio | ★ $6.32 | $7.16 |
| Revenue Growth | 20.19 | ★ 62.63 |
| 52 Week Low | $3.73 | $16.52 |
| 52 Week High | $10.32 | $25.15 |
| Indicator | AVAH | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 46.41 |
| Support Level | $6.11 | $20.56 |
| Resistance Level | $6.93 | $24.45 |
| Average True Range (ATR) | 0.28 | 0.61 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 45.06 | 7.00 |
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.